Carman J, Peuskens J, Vangeneugden A
Carman Research, Atlanta, GA 30339, USA.
Int Clin Psychopharmacol. 1995 Nov;10(4):207-13. doi: 10.1097/00004850-199511000-00001.
Risperidone has antiserotonergic and antidopaminergic properties that may make it more effective than conventional antipsychotic agents in the treatment of the negative symptoms of schizophrenia. Clinical trials in chronic schizophrenic patients have shown trends in favor of risperidone in the control of negative symptoms compared with haloperidol, perphenazine or zuclopenthixol, but the differences were not consistently statistically significant. A meta-analysis of the pooled results from six double-blind trials showed that risperidone at doses ranging from 4 to 8 mg/day had a significantly (p < 0.004) higher negative symptom response rate, defined as the percentage of patients with a 20% or more reduction in scores on the negative subscale of the Positive and Negative Syndrome Scale, than patients receiving active controls. The combined patient population treated with 4-8 mg/day of risperidone was 1.43 times more likely to have had a clinical response on the negative symptom subscale than the combined population treated with haloperidol, perphenazine or zuclopenthixol.
利培酮具有抗5-羟色胺能和抗多巴胺能特性，这可能使其在治疗精神分裂症阴性症状方面比传统抗精神病药物更有效。对慢性精神分裂症患者的临床试验表明，与氟哌啶醇、奋乃静或氯噻吨相比，利培酮在控制阴性症状方面有一定优势，但差异在统计学上并不始终显著。对六项双盲试验汇总结果的荟萃分析显示，每日剂量为4至8毫克的利培酮，其阴性症状缓解率（定义为阳性和阴性症状量表阴性分量表得分降低20%或更多的患者百分比）显著高于接受活性对照的患者（p < 0.004）。每日服用4 - 8毫克利培酮的患者群体在阴性症状分量表上出现临床反应的可能性是服用氟哌啶醇、奋乃静或氯噻吨的患者群体的1.43倍。
